| Efficacy and safety of lenalidomide combined with rituximab in the treatment of grade 1-3a follicular lymphoma patients |
| Received:August 12, 2020 Revised:August 20, 2020 Click here to download the full text |
| Citation of this paper:REN Yu-hong,WANG Wei-guang,CHENG Zhi-xiang,CHENG Lu-ya,KE Yang,ZHUANG Jing-li,WEI Zheng,LIU Peng.Efficacy and safety of lenalidomide combined with rituximab in the treatment of grade 1-3a follicular lymphoma patients[J].Chinese Journal of Clinical Medicine,2020,27(5):756-760 |
| Hits: 1338 |
| Download times: 495 |
| Author Name | Affiliation | E-mail | | REN Yu-hong | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | WANG Wei-guang | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | CHENG Zhi-xiang | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | CHENG Lu-ya | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | KE Yang | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | ZHUANG Jing-li | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | WEI Zheng | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | LIU Peng | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | liu.peng@zs-hospital.sh.cn |
|
| Abstract:Objective: To explore the efficacy and safety of lenalidomide combined with rituximab in the treatment of grade 1-3a follicular lymphoma (FL) patients. Methods: Twelve FL patients received lenalidomide combined with rituximab (R2) in Department of Hematology of Zhongshan Hospital, Fudan University between May 30, 2019 and Dec 31, 2019 were selected. Treatment with R2 consisted of lenalidomide 25 mg: d 1-7, d 15-22 on cycle 1-12, orally, and R2 375 mg/m2: d 1, 8, 15, 22 on cycle 1 and d 1 on cycle 2-5, intravenously. Every 28 days was one cycle. Efficacy was assessed every 2 to 3 cycles during the treatment. Efficacy was analyzed by overall response rate (ORR) and progression-free survival (PFS). Safety was assessed before and after each cycle. Results: Among 12 patients received R2 regimen, the efficacy in 10 patients was evaluable, the ORR was 88.9%. One-year rate of PFS was 87.5% and median PFS was not reached. Grade 3-4 neutropenia and grade 3-4 pulmonary infection rates were both 16.7% (2/12). Grade 3-4 liver or renal function abnormality, rash, digestive symptoms, and peripheral nervous disease were not observed. Conclusions: Lenalidomide combined with R2 is generally effective and safe in both untreated and relapsed grade 1-3a FL patients. |
| keywords:lenalidomide rituximab follicular lymphoma efficacy safety |
| HTML View Full Text View/Add Comment Download reader |
|
|
|